阿尔茨海默病和糖尿病相关的认知功能障碍:微质链接?
Yaqiong Liu1, Tao Li1, Juliang Xiong2
1Regenerative Medicine Institute (REMEDI), Biomedical Sciences Building, University of Galway, Galway, Ireland.
Metabolic brain disease
|January 4, 2025
概括
在阿尔茨海默病 (AD) 和糖尿病相关认知功能障碍 (DACD) 鼠标模型中,微质的频率增加. 这项研究揭示了不同的微质子类型和通信网络,为向治疗提供了洞察力.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 基因组学就是基因组学.
背景情况:
- 阿尔茨海默病 (AD) 涉及粉样β斑块和团,导致痴呆.
- 糖尿病相关的认知功能障碍 (DACD) 与糖尿病中认知和记忆障碍有关.
- 微质在AD和DACD中都起作用,但它们在这些疾病中的特定特征尚不清楚.
研究的目的:
- 为了研究阿尔茨海默病和糖尿病相关的认知功能障碍小鼠模型中的微质变化.
- 为了比较AD和DACD模型之间的微质频率,基因表达,细胞-细胞通信和亚型.
- 在AD和DACD中确定基于微质的干预措施的潜在治疗点.
主要方法:
- 利用来自公开可用的数据集的单核RNA测序 (snRNA-Seq) 数据.
- 进行生物信息学分析以评估微质频率,基因表达和细胞间相互作用.
- 在5XFAD (AD模型) 和db/db (DACD模型) 小鼠中分析了微质子类型和转录因子活性.
主要成果:
- 与对照组相比,AD和DACD小鼠模型中的微质频率都增加了.
- 从这两种疾病模型中,微质中只发现了六种常见的上调基因.
- 细胞聊天分析表明,AD和DACD中的微质细胞具有独特的细胞-细胞通信网络.
- 在5XFAD和db/db小鼠之间观察到微质子类型和转录因子概况的显著差异.
结论:
- 这项研究为AD和DACD的微质异质性和功能提供了新的见解.
- 这些发现突出了AD和DACD之间的微质反应的差异.
- 鉴定到的变化表明了为两种疾病开发微质向治疗的潜在途径.
相关概念视频
Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
Psychoneuroimmunology: Diabetes and Cancer
22
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
22
Alzheimer's Disease: Treatment
161
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
161
Role of Neurotransmitters in Memory
420
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
420
Dementia
94
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
94


